Spero Therapeutics, Inc. Available-for-sale Securities, Amortized Cost Basis
Spero Therapeutics, Inc. (SPRO) had Available-for-sale Securities, Amortized Cost Basis of $90.77 million as of 2018-09-30, per its 10-Q filed 2018-11-08.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesAmortizedCost · last filed 2018-11-08
- 2018-09-30: Available-for-sale Securities, Amortized Cost Basis $90.77M.
- 2018-06-30: Available-for-sale Securities, Amortized Cost Basis $17.94M.
- 2018-03-31: Available-for-sale Securities, Amortized Cost Basis $22.87M.
| Period end | Available-for-sale Securities, Amortized Cost Basis |
|---|---|
| 2018-09-30 | $90.77M 10-Q · filed 2018-11-08 |
| 2018-06-30 | $17.94M 10-Q · filed 2018-08-09 |
| 2018-03-31 | $22.87M 10-Q · filed 2018-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 |